1-(4-Chloropicolinoyl)piperidine-3-carboxylic acid

Catalog No.: 
ACWNRL207
CAS No.: 
1154331-74-4
Molecular Formula: 
C12H13ClN2O3
Molecular Weight: 
268.70
1-(4-Chloropicolinoyl)piperidine-3-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$431.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(4-Chloropicolinoyl)piperidine-3-carboxylic acid
IUPAC Name1-(4-chloropicolinoyl)piperidine-3-carboxylic acid
MDL No.MFCD12094729
Molecular FormulaC12H13ClN2O3
Molecular Weight268.70
SMILESO=C(C1CN(C(C2=NC=CC(Cl)=C2)=O)CCC1)O
InChI KeySDQFRNUOTFDPPP-UHFFFAOYSA-N
Synonym1-[(4-Chloro-2-pyridinyl)carbonyl]-3-piperidinecarboxylic acid;1-(4-CHLOROPICOLINOYL)PIPERIDINE-3-CARBOXYLIC ACID;3-Piperidinecarboxylic acid, 1-[(4-chloro-2-pyridinyl)carbonyl]-
CAS No.1154331-74-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACWNRL207 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJRFB624 route compound structure diagram
    ACJRFB62453750-66-6In Stock
  2. Plus
  3. ACEJHQ928 route compound structure diagram
    ACEJHQ928498-95-3In Stock
  4. Then
  5. ACWNRL207 route product structure diagram
    ACWNRL2071154331-74-4
Inquiry

2. ACWNRL207 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWNRL207 route product structure diagram
    ACWNRL2071154331-74-4
Inquiry

3. ACWNRL207 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWNRL207 route product structure diagram
    ACWNRL2071154331-74-4
Inquiry

Comments (0)